Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 July 1991

Next earnings report:

05 February 2025

Last dividends:

N/A

Next dividends:

N/A
$115.19 B
-13%vs. 3y high
99%vs. sector
-vs. 3y high
-vs. sector
-17%vs. 3y high
88%vs. sector
-14%vs. 3y high
79%vs. sector

Price

pre-market | 32 min ago
$447.27-$3.08(-0.68%)

Dividend

No data over the past 3 years
$2.77 B$2.78 B
$2.77 B$1.05 B

Analysts recommendations

Institutional Ownership

VRTX Latest News

Got $500? 1 Biotech Stock to Buy and Hold Forever
fool.com22 November 2024 Sentiment: POSITIVE

Do you have $500? Here's one biotech stock you should consider buying and keeping for the long term.

Buy Signal Flashing For Struggling Biotech
forbes.com20 November 2024 Sentiment: NEGATIVE

Biotech company Vertex Pharmaceuticals (VRTX) has faced challenges in the stock market recently, affecting its 10% gain for the year. After a 5.6% increase following its earnings report earlier this month, the stock has lost that momentum and is now at its lowest point since June.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
zacks.com19 November 2024 Sentiment: POSITIVE

Lately, users of Zacks.com have been focusing on Vertex (VRTX). This interest prompts a closer look at what the stock might offer.

Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
seekingalpha.com15 November 2024 Sentiment: POSITIVE

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 9:00 AM ET. The company will be represented by Dr. Reshma Kewalramani, who is the President and CEO. Debjit Chattopadhyay from Guggenheim Partners will host the event and welcome Dr. Kewalramani.

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
fool.com13 November 2024 Sentiment: POSITIVE

Regulators are examining a drug that has the potential to be worth billions of dollars.

Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average
zacks.com06 November 2024 Sentiment: POSITIVE

Vertex Pharmaceuticals (VRTX) has hit an important support level, making it an attractive option for investors based on technical analysis. The stock recently surpassed the 20-day moving average, indicating a positive trend in the short term.

Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors
zacks.com06 November 2024 Sentiment: POSITIVE

From a technical viewpoint, Vertex Pharmaceuticals (VRTX) appears to be an appealing choice since it has just hit an important support level. VRTX has recently surpassed the 50-day moving average, indicating a positive trend in the short term.

Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com05 November 2024 Sentiment: POSITIVE

The main figures for Vertex (VRTX) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be helpful to look at some of its important metrics in relation to Wall Street predictions and last year's results.

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
zacks.com28 October 2024 Sentiment: NEUTRAL

Vertex Pharmaceuticals (VRTX) finished the most recent trading session at $476.37, which is a decrease of 0.28% compared to the previous day.

The Smartest Growth Stock to Buy With $500 Right Now
fool.com25 October 2024 Sentiment: POSITIVE

This stock may not stay below $500 for much longer.

What type of business is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of drug therapies for cystic fibrosis (CF) and other serious diseases. It was founded in 1989. Currently, the company's product portfolio includes medications such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. These three drugs combined are approved for the treatment of approximately half of the 75,000 CF patients in North America, Europe, and Australia.

What sector is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated is in the Healthcare sector

What industry is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated is in the Biotechnology industry

What country is Vertex Pharmaceuticals Incorporated from?

Vertex Pharmaceuticals Incorporated is headquartered in United States

When did Vertex Pharmaceuticals Incorporated go public?

Vertex Pharmaceuticals Incorporated initial public offering (IPO) was on 24 July 1991

What is Vertex Pharmaceuticals Incorporated website?

https://www.vrtx.com

Is Vertex Pharmaceuticals Incorporated in the S&P 500?

Yes, Vertex Pharmaceuticals Incorporated is included in the S&P 500 index

Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?

Yes, Vertex Pharmaceuticals Incorporated is included in the NASDAQ 100 index

Is Vertex Pharmaceuticals Incorporated in the Dow Jones?

No, Vertex Pharmaceuticals Incorporated is not included in the Dow Jones index

When was Vertex Pharmaceuticals Incorporated the previous earnings report?

No data

When does Vertex Pharmaceuticals Incorporated earnings report?

The next expected earnings date for Vertex Pharmaceuticals Incorporated is 05 February 2025